• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   DSpace@Amasya
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
  •   DSpace@Amasya
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • WoS İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Examination of the specific clinical symptoms and laboratory findings of Crimean-Congo hemorrhagic fever

Erişim

info:eu-repo/semantics/openAccess

Tarih

2016

Yazar

Kilinc, Cetin
Guckan, Ridvan
Capraz, Mustafa
Varol, Kenan
Zengin, Erman
Mengeloglu, Zafer
Menekse, Elif

Üst veri

Tüm öğe kaydını göster

Özet

Background & objectives: Crimean-Congo hemorrhagic fever (CCHF) is a fatal disease, caused by a tick-borne virus (Nairovirus), having a high mortality rate. The study was aimed to evaluate the risk factors, the presenting symptoms and findings of the patients with prediagnosis of CCHF disease, and to compare these variables between the CCHF-positive and CCHF-negative patients. It was also aimed to develop a scoring formula for the diagnosis of CCHF. Methods: In total, 281 patients who were admitted to the Sabuncuoglu Serafeddin Training and Research Hospital, Amasya, Turkey between 2011 and 2015 and were prediagnosed with CCHF based on the clinical symptoms, laboratory findings and risk factors were included in the study. The definitive laboratory diagnosis of patients with prediagnosis of CCHF was ensured via molecular and serological methods. In addition, a mathematical diagnostic scoring formula was developed for enhancing the laboratory results of CCHF. Results: The ratio of certain clinical symptoms such as fever (p<0.001), headache (p<0.001), widespread body pain (p<0.001), fatigue (p = 0.001), nausea and vomiting (p = 0.013) in CCHF-positive patients were found to be significantly higher compared to the ratio in CCHF-negative patients. In terms of laboratory findings such as presence of leucopenia (p<0.001), creatine kinase (CK) elevation (p<0.001), thrombocytopenia (p<0.001), aspartate aminotransferase/alanine aminotransferase (AST/ALT) elevation (p<0.001), lactate dehydrogenase (LDH) levels (p = 0.002), absence of abnormal findings on chest radiograph (p = 0.042), and the absence of anaemia (p = 0.007), the CCHF-positive patients had higher rates in comparison to CCHF-negative ones. Interpretation & conclusion: It was inferred that certain clinical symptoms and laboratory findings such as fever, headache, widespread body pain, fatigue, leucopenia, nausea, vomiting, high CK levels, thrombocytopenia, AST/ALT elevation and elevated LDH levels are highly specific and are required to be considered in the definitive diagnosis of CCHF, particularly in regions where this infection is observed as endemic.

Kaynak

JOURNAL OF VECTOR BORNE DISEASES

Cilt

53

Sayı

2

Bağlantı

https://hdl.handle.net/20.500.12450/1201

Koleksiyonlar

  • WoS İndeksli Yayınlar Koleksiyonu [2182]



DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 




| Yönerge | Rehber | İletişim |

DSpace@Amasya

by OpenAIRE
Gelişmiş Arama

sherpa/romeo

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreBölüme GöreYayıncıya GöreKategoriye GöreDile GöreErişim ŞekliBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreBölüme GöreYayıncıya GöreKategoriye GöreDile GöreErişim Şekli

Hesabım

GirişKayıt

DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 


|| Yönerge || Rehber || Kütüphane || Amasya Üniversitesi || OAI-PMH ||

Amasya Üniversitesi Kütüphane ve Dokümantasyon Daire Başkanlığı, Amasya, Turkey
İçerikte herhangi bir hata görürseniz, lütfen bildiriniz: openaccess@amasya.edu.tr

Creative Commons License
DSpace@Amasya by Amasya University Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@Amasya: